ProfG warned about not being an Ostrich in case you get bitten in the Arse/Ass.
So all together.
Mousey Shark Do Do…Do…DoDo; Mousey, Mousey Shark DoDo…Do…DoDo; Mousey, Mousey Shark DoDo…Do…DoDo; Mousey Shark
The CD20 wars are going to ramp up and COVID-19 could be just one battle ground that makes the difference. Ocrelizumab has been flying high in the MS_DMT charts. You know Pharma they like a slice of the pie and they hunt in packs
Here we go….Pharma Shark Do Do…Do…DoDo; Pharma Shark DoDo…Do…DoDo; Pharma Shark DoDo…Do…DoDo; Pharma Shark
The makers for ocrelizumab and rituximab are also the makers of a machine that goes ping and have FDA approval to test antibodies against SARS-CoV-2. Therefore they are a perfect place to monitor all their patients on ocrelizumab/rituximab to see if they have made an anti-viral response. Are they going to do it…probably they will have to because if they don’t someone else will do it…But would you trust them?
After all they have done vaccine trials and despite being reported they have not published their in a Peer-reviewed journal, possibly because surprisng surprise, your vaccine responses are not that great. Rule number 1 in Pharma land…don’t SH1 on yourself.
So here we go Mousey Shark Do Do…Do…DoDo; Mousey, Mousey Shark DoDo…Do…DoDo; Mousey, Mousey Shark DoDo…Do…DoDo; Mousey Shark
We have predicted that you don’t need B cells and antibody to get did of the virus, but immunology 101 says it is part of the defence machinery and the important point is what happens next time you get infected. If you have an intact immune response and viral immunity, nothing happens or the symptomatic problems are blunted.
In Monkeys re-infected they showed mild symptoms for a day and the virus was gone. If fact it never got started and these monkeys all had a rip-roaring antibody response
Now the World Health Organisation have started to cause SH1 by saying don’t issue anti-viral passports because we don’t know if immunity will stop re-infection, but immunology101 says this can happen and what evidence is there that you can get re-infected and show severe symptoms?.
We have heard alot about finding virus again, but the simple logic is this is not a re-infection but the infection never went away…we know you are producing virus for over 2 weeks after you have not been sheeding from your nose. I know someone who when to hospital twice once for 3 days and then about a week later for a week. Had they been re-infected? I doubt it. Do people harbour more than one virus I have seen evidence of this. Maybe wrong you can give me the references as oposed to the newspaper cuttings
So the question is if you are B cell depleted will you show re-infection and can you mount an anti-viral B cell response and if you do is it good enough. Why the concern because people treated with rituximab have a reduced vaccine response and this occurs with ocrelizumab too. This may be important if a COVID-19 vaccine occurs
Does this surprise me. The anwer is no. This because there is marked depletion of the B cells that are going to make the new responses. If you stop ocrelizumab these take about 60-70 weeks to recover. The question is how many do yu need to give a good vaccine response. Recovery with ofatumumab another anti-CD20 antibody in late stage development is much, much quicker because they use a low dose injected every week. This is not without potential issues.
However, is this going to be more vaccine ready and importantly what will this do to vaccinations?. The trial is ongoing NCT03650114 and it is involving 2010 people and guess what it was posted in 2018 with an end date of 2025, but the info says they actually started in 2010. So now is the time to crack the code…fear not it will be in the label even if it is not reported in a peer review paper ready for when the drug is approved. Will it give ofatumumab the edge….. I guess this approach is likely to give ocrelizumab a new patent as they are plugging the subcutaneous dosing hole (NCT03972306) with a trial testing 40-1200mg. They also did a trial to see if the infusion can be done quicker (NCT03085810). This is being review by the FDA. So it is all go on the B cell front. This will uncover biology.
However this may all be hypothetical. And could all be irrelevant.
Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS. Novi G, Ivaldi F, Sbragia E, Mikulska M, Pesce G, Inglese M, Kerlero de Rosbo N, Uccelli A. Neurol Neuroimmunol Neuroinflamm. 2020 Feb 25;7(3). pii: e695.
This person developed chickenpox 3 months after the first round of ocrelizumab induced depletion. They developed antibodies to the infection. So it may occur for SAR-Cov2. We have to wait and see.
PET PEEVE….Now today is a holiday in the UK, and if you have your Union Flag out remember….PUT IT THE RIGHT WAY UP! THE WIDE WHITE BIT ON THE DIAGONAL IS BIGGEST AT THE THE TOP NEXT TO THE FLAG POLE….
It is amazing who gets it wrong. I remember the Association of British Universities got it wrong. That’s what happens when you have eyes on your flags, rather than a rope and toggle. I went to a meeting is a Dutch town and the flags there were upside down in a American Chain Hotel, I complained and they said it was a mistake, I then went to Streetview and showed them using the different years that it changed when Brexit arrived….Pathetic….Yes I am a pedantic.
If this Odd?